NovaBridge Biosciences

NASDAQ:NBP

Biotechnology

Healthcare
$0.90 -4.78%

-$0.07 today

Market cap
$104.10M
Beta
1.48
P/E (TTM)
-25.5
EPS (TTM)
-$0.40
52W Low $1.46High $6.79

Volume 0.87M

Average 0.90M

NBP Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

NovaBridge BiosciencesNASDAQ: NBP

Selling, General & Admin · Q4 FY2025 · quarter ended Dec 2025

Selling, general & admin dips below year-ago levels

Q4 FY2025 selling, general & admin of $2.46M fell 66.4% year over year, behind the +128.2% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 57.6% from the prior quarter. Over 3 fiscal years it compounded at -71.8% a year.

Context

  • Selling, general & admin increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the -97.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
$2.46M-57.6% QoQ
Last fiscal yearDec 2025
$4.48M-97.9% YoY
LTMSep 2025
$21.46M+128.2% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-66.4%-100.0%-33.6 pp
1 year-97.9%-100.0%-2.1 pp
3-year CAGR-71.8%+233.2%+305.0 pp
5-year CAGR+172.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

Mixed currencies · from the income statement

Latest · FY2025
4.48M USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How NBP compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +128.2% is the highest of 10, against a peer median of +11.6%.
  • Over three fiscal years its annual growth of -71.8% compares with a peer median of +10.7%.
NBP Competitors
Selling, General & Admin for NBP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$75.11M USD-30.1%+13.7%—
ENGNenGene Holdings Inc.LTM Apr 2026$35.41M USD+41.6%+106.4%—
ANNXAnnexon, Inc.LTM Mar 2026$32.75M USD-0.8%+0.8%—
ALTAltimmune, Inc.LTM Mar 2026$30.16M USD+39.3%+17.9%83769.4%
AURAAura Biosciences, Inc.LTM Mar 2026$23.71M USD+3.3%+7.6%—
NBPNovaBridge BiosciencesLTM Sep 2025CN¥21.46M CNY+128.2%-71.8%—
DSGNDesign Therapeutics, Inc.LTM Mar 2026$20.62M USD+11.6%+2.3%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$18.21M USD—+110.6%—
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$10.42M USD+13.5%-3.1%—
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$9.79M USD+21.7%+16.7%—
GALTGalectin Therapeutics Inc.LTM Mar 2026$6.23M USD+9.7%-4.3%—
Peer median (excluding NBP) —+11.6%+10.7%83769.4%

Competitors are the stored peer set for NBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CNY
FY2022
Dec 2022 · CNY
FY2023
Dec 2023 · CNY
FY2024
Dec 2024 · CNY
FY2025
Dec 2025 · USD
Revenue88.03M(10.7M)4.49M00
Cost of Revenue46.43M0000
Gross Profit41.59M(10.7M)4.49M00
Gross Margin47.3%100.0%100.0%——
Research & Development190.29M155.51M114.36M158.9M8.99M
Selling, General & Admin899.94M199.88M63.91M216.46M4.48M
Operating Expenses2.11B355.38M515.65M375.36M13.48M
Depreciation & Amortization13.78M1.42M3.37M1.91M122.37K
EBITDA(2.06B)(51.23M)(344.25M)(373.45M)(13.35M)
EBITDA Margin-2337.4%478.9%-7674.2%——
Operating Income(2.07B)(366.08M)(511.16M)(375.36M)(13.48M)
Operating Margin-2353.1%3422.2%-11395.1%——
Interest Income21.33M4.95M7.3M54.64M1.09M
Interest Expense00101.85K00
Other Income / Expenses(260.73M)(607.09M)(954.53M)12.63M847.61K
Income Before Tax(2.33B)(973.17M)(1.47B)(362.73M)(12.63M)
Pre-Tax Margin-2649.3%9097.4%-32674.0%——
Income Tax Expense(494.81K)710.39K(1.26B)00
Net Income(2.33B)(2.51B)(1.47B)(162.26M)(6.61M)
Net Margin-2648.7%23438.9%-32674.0%——
EPS (Basic)(30.70)(30.38)(17.62)(4.46)(0.16)
EPS (Diluted)(30.68)(30.38)(17.62)(4.46)(0.16)
Weighted Avg Shares75.93M82.52M83.19M81.19M41.64M
Weighted Avg Shares (Diluted)75.96M82.52M83.23M81.19M41.64M

NovaBridge Biosciences

NASDAQ:NBP

Intrinsic Alpha fair value

Locked

Current Price

$0.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.